Occult hepatitis B virus infection is not associated with disease progression of chronic hepatitis C virus infection

Table 2 Comparison of clinical factors between patients with and without occult hepatitis B virus infection

Variable	OBI (+) (n = 32)	OBI (-) (n = 142)	P value
Mean age, yr	67.1 ± 9.6	66.4 ± 9.9	0.952
Male sex	19 (59.4)	86 (60.6)	0.527
Body mass index (kg/m2)	23.9 ± 3.2	23.2 ± 3.0	0.180
Anti-HBc (n = 100)	6 (66.7)	69 (75.8)	0.399
Anti-HBs (n = 157)	14 (48.3)	72 (56.3)	0.283
Hemoglobin (g/mL)	13.3 ± 1.3	13.5 ± 1.9	0.364
Platelet (× 103/mL)	150.5 ± 79.5	151.5 ± 89.3	0.978
Albumin (g/dL)	3.9 ± 0.5	4.0 ± 0.4	0.593
Total bilirubin (mg/dL)	1.1 ± 0.8	1.0 ± 0.5	0.118
AST (IU/L)	62.7 ± 40.3	78.8 ± 112.6	0.546
ALT (IU/L)	54.7 ± 43.5	82.2 ± 151.6	0.148
Creatinine (mg/dL)	0.9 ± 0.2	0.9 ± 0.4	0.779
PT-INR	1.0 ± 0.1	1.0 ± 0.1	0.459
MELD score	8.3 ± 1.9	8.6 ± 2.4	0.744
HCV genotype (1/2)	12/15 (44.4%/55.6%)	48/60 (44.4%/55.6%)	0.587
AFP > 20 ng/mL	6 (19.4)	23 (16.5)	0.441
Child-Pugh class			0.436
A	28 (87.5)	132 (93.0)
B	4 (12.5)	8 (5.6)
C	0	2 (1.3)
Antiviral treatment
No antiviral treatment	21 (65.6)	81 (57.0)	0.430
Treatment without SVR	5 (19.2)	29 (26.4)	0.616
Treatment with SVR	6 (18.8)	32 (22.5)	0.814
Disease progression	7 (21.9)	45 (31.7)	0.392
Development of HCC	3 (11.5)	11 (10.6)	1.000
Follow-up period (mo)	42.5 ± 34.7	36.3 ± 26.9	0.555

Data are presented as mean ± SD or number (%). OBI: Occult hepatitis B virus infection; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; MELD: Model for end-stage liver disease; HCV: Hepatitis C virus; AFP: Alpha-fetoprotein; PT-INR: Prothrombin time-international normalized ratio; SVR: Sustained virologic response.